PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28373436
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines.
PG  - 1737-1745
AB  - BACKGROUND/AIM: This study aimed to evaluate the in vitro efficacy of carboplatin
      and piroxicam, both in isolation and combined, against T24 and 5637 human urinary
      bladder cancer cell lines. MATERIALS AND METHODS: Cell viability, drug
      interaction, cell morphology, cell proliferation, apoptosis and autophagy were
      analyzed after 72 h of drug exposure. Statistical analysis was performed and
      values of p<0.05 were considered statistically significant. RESULTS: Drug
      exposure in combination led to a significant reduction of cell viability
      comparatively to single-drug exposure. These combinations resulted in a
      synergistic interaction in the T24 (combination index for 50% effect (CI50)=0.65)
      and 5637 (CI50=0.17) cell lines. Notable increase of morphological alterations, a
      marked decrease of Ki-67 expression, a considerable enhancement of autophagic
      vacuoles and a minimal effect on apoptosis was observed in both cell lines
      treated with combined drugs. CONCLUSION: Data showed that in vitro combination of
      carboplatin and piroxicam produced a more potent antiproliferative effect when
      compared to single drugs.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Silva, Jessica
AU  - Silva J
AD  - Department of Veterinary Sciences, Hospital Center of Tras-os-Montes and Alto
      Douro, Vila Real, Portugal.
FAU - Arantes-Rodrigues, Regina
AU  - Arantes-Rodrigues R
AD  - Center for the Research and Technology of Agro-Environmental and Biological
      Sciences (CITAB), Hospital Center of Tras-os-Montes and Alto Douro, Vila Real,
      Portugal.
AD  - Cytogenetic Laboratory, Hospital Center of Tras-os-Montes and Alto Douro, Vila
      Real, Portugal.
FAU - Pinto-Leite, Rosario
AU  - Pinto-Leite R
AD  - Cytogenetic Laboratory, Hospital Center of Tras-os-Montes and Alto Douro, Vila
      Real, Portugal.
AD  - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 
      Porto, Portugal.
FAU - Faustino-Rocha, Ana I
AU  - Faustino-Rocha AI
AD  - Center for the Research and Technology of Agro-Environmental and Biological
      Sciences (CITAB), Hospital Center of Tras-os-Montes and Alto Douro, Vila Real,
      Portugal.
AD  - Faculty of Veterinary Medicine, Lusophone University of Humanities and
      Technologies, Lisbon, Portugal.
FAU - Fidalgo-Goncalves, Lio
AU  - Fidalgo-Goncalves L
AD  - Institute for Systems and Computer Engineering, Technology and Science
      (INESC-TEC), University of Tras-os-Montes and Alto Douro, Vila Real, Portugal.
FAU - Santos, Lucio
AU  - Santos L
AD  - Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 
      Porto, Portugal.
AD  - Health School, University Fernando Pessoa, Porto, Portugal.
AD  - Medical Oncology Department, Portuguese Institute of Oncology, Porto, Portugal.
FAU - Oliveira, Paula A
AU  - Oliveira PA
AD  - Department of Veterinary Sciences, Hospital Center of Tras-os-Montes and Alto
      Douro, Vila Real, Portugal [email protected]
AD  - Center for the Research and Technology of Agro-Environmental and Biological
      Sciences (CITAB), Hospital Center of Tras-os-Montes and Alto Douro, Vila Real,
      Portugal.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antineoplastic Agents)
RN  - 13T4O6VMAM (Piroxicam)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Carboplatin/*pharmacology
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/drug effects
MH  - *Drug Synergism
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Piroxicam/*pharmacology
MH  - Tumor Cells, Cultured
MH  - Urinary Bladder Neoplasms/drug therapy/*pathology
OTO - NOTNLM
OT  - *Carboplatin
OT  - *piroxicam
OT  - *synergistic effect
OT  - *urinary bladder cancer cell lines
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/13 [received]
PHST- 2017/03/09 [revised]
PHST- 2017/03/13 [accepted]
AID - 37/4/1737 [pii]
AID - 10.21873/anticanres.11506 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1737-1745.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>